We are live on ! Find out more
RNAM

Avidity Biosciences
RNAM

Delisted

RNAM was delisted on the 26th of February, 2026.

Back to rankings

144 hedge funds and large institutions have $701M invested in Avidity Biosciences in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 47 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more call options, than puts

Call options by funds: $756K | Put options by funds: $345K

34% more capital invested

Capital invested by funds: $522M → $701M (+$179M)

13% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 47

1% more funds holding

Funds holding: 142 → 144 (+2)

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5.84% less ownership

Funds ownership: 110.3% → 104.46% (-5.8%)

Holders
144
Holders Change
+2
Holders Change %
+1.41%
% of All Funds
2.1%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
53
Reduced
47
Closed
23
Calls
$756K
Puts
$345K
Net Calls
+$411K
Net Calls Change
-$176K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$12.2M
2
LGM
Logos Global Management
California
+$5.18M
3
BlackRock
BlackRock
New York
+$4.75M
4
Deutsche Bank
Deutsche Bank
Germany
+$4.2M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.01M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$26.5M
2
CAM
Cormorant Asset Management
Massachusetts
-$11.2M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$5.37M
4
State Street
State Street
Massachusetts
-$4.83M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$94.2M -$4.75M -710,335 -6%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$62.6M +$1.98M +296,238 +4%
RI
3
RTW Investments
New York
$60.5M – – –
BlackRock
4
BlackRock
New York
$58.8M +$4.75M +710,018 +12%
CAC
5
Cowen and Company
New York
$50.9M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$36.6M +$192K +28,689 +0.7%
State Street
7
State Street
Massachusetts
$31.1M -$4.83M -721,964 -17%
Morgan Stanley
8
Morgan Stanley
New York
$27M +$12.2M +1,823,904 +158%
ACA
9
Avoro Capital Advisors
New York
$22.7M – – –
RCM
10
RA Capital Management
Massachusetts
$22.2M -$26.5M -3,962,465 -62%
Artisan Partners
11
Artisan Partners
Wisconsin
$19M -$340K -50,876 -2%
Adage Capital Partners
12
Adage Capital Partners
Massachusetts
$14.5M +$2.01M +300,000 +23%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$14M +$746K +111,661 +8%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$13.6M -$609K -91,101 -6%
Balyasny Asset Management
15
Balyasny Asset Management
Illinois
$11M -$5.37M -804,053 -40%
CC
16
Casdin Capital
New York
$10.6M -$496K -74,250 -6%
BC
17
Boxer Capital
California
$10.1M – – –
JP Morgan Chase
18
JP Morgan Chase
New York
$8.76M -$18.7K -2,799 -0.3%
ACM
19
Alethea Capital Management
Washington
$7.73M – – –
LGM
20
Logos Global Management
California
$7.01M +$5.18M +775,000 New
Deutsche Bank
21
Deutsche Bank
Germany
$6.9M +$4.2M +628,299 +467%
Two Sigma Investments
22
Two Sigma Investments
New York
$6.04M +$696K +104,191 +18%
5VM
23
5AM Venture Management
California
$6.02M – – –
Northern Trust
24
Northern Trust
Illinois
$6M +$151K +22,524 +4%
Charles Schwab
25
Charles Schwab
California
$4.94M +$205K +30,674 +6%
1
2 3 4 5

RNAM Hedge Fund Activity: Q4 2023 in Review

144 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2023, worth a combined $701M — up 34% from $522M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new RNAM positions and 23 closed out — a net gain of 2 holders — while 53 added to existing stakes and 47 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $12.2M. The largest seller was RA Capital Management, cutting an estimated $26.5M.

  • 144 institutional investors held Avidity Biosciences (RNAM) as of Q4 2023, up from 142 in Q3 2023.
  • Funds reported $701M of Avidity Biosciences stock for Q4 2023, up 34% quarter-over-quarter.
  • 25 funds opened new Avidity Biosciences positions in Q4 2023 and 23 closed out, a net change of +2 holders.
  • The largest Avidity Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $12.2M added.
  • The largest Avidity Biosciences seller in Q4 2023 was RA Capital Management, an estimated $26.5M sold.

Based on aggregated 13F filings for Q4 2023.